Frenaver SA
0.5 FTEFrenaver reported total assets of 418,862 € at the end of the 2025 financial year (annual accounts filed with the NBB on 13 Jul 2026), with 0.5 full-time equivalent.
The score of Frenaver shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +9 % Total assets +69 % Headcount (avg FTE) -55 %
Accounts of the company itself (not consolidated).
The full file covers 18 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Frenaver's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 13 Jul 2026
- Year ended 31 Dec 2024filed on 04 Jun 2025
- Year ended 31 Dec 2023filed on 03 Jun 2024
- Year ended 31 Dec 2022filed on 13 Jun 2023
- Year ended 31 Dec 2021filed on 17 Jun 2022
Frenaver's financial analysis
- Solvency52.4%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Frenaver
Frenaver's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0461.238.364
- VAT number
- BE0461238364
- Peppol
- Registered · 0208:0461238364 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 12 Aug 1997
- Registered office
- 2220 Heist-op-den-Berg
- Size
- Micro · 0.5 FTE
- Latest accounts
- 2025 · filed on 13 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Frenaver (SA) has been based in Heist-op-den-Berg since 1997, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 9,694 € and equity of 219,487 €; its revenue is not published. With 0.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 52.4%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Frenaver
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Callebaut Retail sale of pharmaceutical products Ghent · balance sheet 418,624 €
- Budin-Conserva Retail sale of pharmaceutical products Roeselare · balance sheet 419,437 €
- Hestia Retail sale of pharmaceutical products Ghent · balance sheet 419,536 €
- Pharmacie Engelbeen Retail sale of pharmaceutical products Evere · balance sheet 417,129 €
- Benatpharma Retail sale of pharmaceutical products Jette · balance sheet 420,772 €
- B.K. Pharma Retail sale of pharmaceutical products Anderlecht · balance sheet 421,476 €
- Coriphar Retail sale of pharmaceutical products Tienen · balance sheet 425,689 €
- Apotheke Bocken Retail sale of pharmaceutical products Eupen · balance sheet 426,403 €
Frequently asked questions about Frenaver
What is the revenue of Frenaver?
Frenaver files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Frenaver?
In Belgium, the VAT number is the company number prefixed with BE: BE0461238364 for Frenaver, if the company is VAT-registered. Its company number (CBE) is 0461.238.364.
Where is the registered office of Frenaver?
According to the CBE register, the registered office of Frenaver is in 2220 Heist-op-den-Berg.
What is the equity of Frenaver?
At the close of the 2025 financial year, the equity of Frenaver amounts to 219,487 €, a solvency of 52.4% of total assets.
How many people work at Frenaver?
0.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Frenaver?
The register lists 1 active mandates at Frenaver. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Frenaver
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →